Hanft Wyatt, Stankiewicz Karita Helen, Khorsandi Nikka, Vohra Poonam, Plotzker Rosalyn
University of California, San Francisco, San Francisco, California, USA.
Clin Microbiol Rev. 2025 Mar 13;38(1):e0008523. doi: 10.1128/cmr.00085-23. Epub 2025 Feb 14.
SUMMARYMore than 40 types of sexually transmitted human papillomavirus (HPV) infect the oropharyngeal and anogenital mucosa-high-risk types are associated with precancerous and cancerous lesions of the cervix, vagina, vulva, penis, anus, and oropharynx, and low-risk types cause non-malignant disease, such as anogenital warts. Though most HPV infections resolve spontaneously, immunodeficiencies may result in persistent infection and increased risk of HPV-related sequelae. The mechanism by which HPV results in malignant transformation is multifaceted, involving interactions with numerous cellular pathways, the host immune system, and potentially the host microbiome. Vaccination against HPV is highly efficacious in the prevention of infection and related sequelae, and there now exist several approved formulations that protect against both high- and low-risk types. Despite the advent of vaccination, early detection and treatment of cervical and anal precancerous lesions continues to be integral to secondary prevention-molecular HPV testing, cytology, and tissue biopsy allow for triaging of patients, after which appropriate treatment with close follow-up can avert cancer development.
摘要
40多种性传播的人乳头瘤病毒(HPV)感染口咽和肛门生殖器黏膜,高危型HPV与子宫颈、阴道、外阴、阴茎、肛门和口咽的癌前病变和癌性病变相关,低危型HPV则引起非恶性疾病,如肛门生殖器疣。虽然大多数HPV感染会自发消退,但免疫缺陷可能导致持续感染,并增加HPV相关后遗症的风险。HPV导致恶性转化的机制是多方面的,涉及与众多细胞途径、宿主免疫系统以及可能的宿主微生物群的相互作用。HPV疫苗接种在预防感染和相关后遗症方面非常有效,目前已有几种获批的制剂可预防高危型和低危型HPV。尽管有了疫苗接种,但子宫颈和肛门癌前病变的早期检测和治疗仍然是二级预防的重要组成部分——分子HPV检测、细胞学检查和组织活检有助于对患者进行分类,在此之后进行适当治疗并密切随访可以避免癌症的发生。